Supplement warning letter
This article was originally published in The Tan Sheet
Executive Summary
Supplements such as Viusid, Kalsis and Oncoxin marketed by Birmingham, Ala.-based Beck Network are unapproved new drugs because of claims Kalsis "can halt and even reverse bone loss" and that Oncoxin contains "anti-cancerous agents with proven efficacy in cancer treatments," a July 19 warning letter to the firm states. FDA cited a total of eight products marketed by the firm and also took issue with the claim "clinical studies have proven Viusid is highly effective for treating HIV/AIDS." The firm must respond to the letter within 15 days of receipt...
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.